Eli Lilly has signed a collaboration with Hong Kong-listed METiS TechBio worth as much as $1.1B in milestones, aimed at steering lipid nanoparticles toward tissues the liver-first delivery field has long failed to reach.
The upfront payment sits in the low double-digit millions, according to terms disclosed by both companies. The remaining value is tied to development, regulatory and commercial milestones, plus tiered single-digit royalties on any product that reaches the market.
What the AI actually designs
METiS will run its AiLNP platform to discover and optimize new ionizable lipids and the delivery systems built around them. Lilly brings discovery, development and commercialization experience, and the two will work under a research program with no named drug candidate yet.
Lipid nanoparticles are the tiny carriers behind a generation of genetic medicines. Given intravenously, conventional versions tend to accumulate in the liver, which makes the heart, lungs and muscle hard to reach. Tissue-specific delivery is one of the field’s most stubborn open problems.
A cheap option on a hard problem
The structure of the deal matters as much as the headline number. Against roughly $14.60B in trailing twelve-month research spending at Lilly, an upfront below $100M reads as an option rather than a purchase, with most of the risk left with the partner.
It also fits a pattern. Lilly bought Engage Bio for up to $202M in May, then signed QurCan Therapeutics in September for genetic medicines aimed at the brain and nerves. METiS is the third delivery-focused bet in about five months, and the Chinese AI drug delivery sector’s latest marquee moment.
